Further studies are warranted to provide a rationale for the use of AnxA6 expression status as a predictive marker for basal-like breast cancer and to identify patients with this breast cancer subtype who are more likely to respond to EGFR-targeted therapies. This evidence concerns the gene ANXA6 and breast carcinoma.